Dogwood Therapeutics, Inc. business relationships
Companies named in Dogwood Therapeutics, Inc.’s 10-K filed 2026-03-18, and public companies whose annual reports name Dogwood Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 19% in its category
- Agent readiness
- 10 / 100
- AI adoption
- 0 / 100
Layers: Peptides
Named in Dogwood Therapeutics, Inc.’s annual report 2
“On September 29, 2025, we entered into an Exclusive Licensing Agreement (the "Licensing Agreement") with Serpin Pharma Inc. ("Serpin Pharma") and Rejuvenation Labs, Inc. ("Rejuvenation" and, together with Serpin Pharma, "Serpin"), pursuant to which Serpin Pharma granted the Company a royalty-free, s...” SEC filing
“...entered into an Exclusive Licensing Agreement (the "Licensing Agreement") with Serpin Pharma Inc. ("Serpin Pharma") and Rejuvenation Labs, Inc. ("Rejuvenation" and, together with Serpin Pharma, "Serpin"), pursuant to which Serpin Pharma granted the Company a royalty-free, sublicensable global licens...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.